Hydroxyfasudil Hydrochloride

• CAT Number: I001972
• CAS Number: 155558-32-0
• Molecular Formula: C₁₄H₁₈ClN₃O₃S
• Molecular Weight: 343.83
• Purity: ≥95%
• Synonyms: 5-(1,4-diazepan-1-ylsulfonyl)-2H-isoquinolin-1-one;hydrochloride
• Target: ROCK
• Solubility: 20 mM in H2O
• Storage: 2-8°C
• IC50: 0.12 uM (ROCK1); 0.17 uM (ROCK2)
• InChI: InChI=1S/C14H17N3O3S.ClH/c18-14-12-3-1-4-13(11(12)5-7-16-14)21(19,20)17-9-2-6-15-8-10-17;/h1,3-5,7,15H,2,6,8-10H2,(H,16,18);1H
• InChIKey: XWWFOUVDVJGNNG-UHFFFAOYSA-N
• SMILES: C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CNC3=O.Cl

Hydroxyfasudil hydrochloride (Cat No.: I001972) is a potent ROCK (Rho-associated protein kinase) inhibitor, effectively suppressing the activities of both ROCK1 and ROCK2 with remarkable IC50 values of 0.73 μM and 0.72 μM, respectively. This compound holds significant promise for research and drug development in the context of ROCK-related pathways and associated physiological processes. For further information or specific inquiries concerning Hydroxyfasudil hydrochloride, please feel free to contact us.

Reference

[1]. Tsutomu Akama, et al. Linking Phenotype to Kinase: Identification of a Novel Benzoxaborole Hinge Binding Motif for Kinase Inhibition and the Development of High Potency Rho-Kinase Inhibitors. JPET Fast Forward. Published on September 18, 2013.
[2]. Satoh S, et al. Evidence of a direct cellular protective effect of Rho-kinase inhibitors on endothelin-induced cardiac myocyte hypertrophy. Biochem Biophys Res Commun. 2012 Jul 27;424(2):338-40.
[3]. Shimizu N, et al. Effects of the Rho kinase inhibitor, hydroxyfasudil, on bladder dysfunction and inflammation in rats with HCl-induced cystitis. Int J Urol. 2013 Feb 19.
[4]. Saito M, et al. Hydroxyfasudil ameliorates penile dysfunction in the male spontaneously hypertensive rat. Pharmacol Res. 2012 Oct;66(4):325-31.
[5]. Zhao J, et al. Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial offasudil versus nimodipine. Neurol Med Chir (Tokyo). 2011;51(10):679-83.